Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
77,937.49
(
-1.42%
)
News Focus
News Focus
Post# of 257579
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 86834

Monday, 07/12/2010 5:37:53 AM

Monday, July 12, 2010 5:37:53 AM

Post# of 257579
Cladribine, Merck KGaA’s oral drug for MS, was approved for marketing in Russia under the brand name, Movectro; Merck plans to launch in Russia after obtaining reimbursement:

http://www.reuters.com/article/idCNLDE66B0GB20100712

Cladribine applications are pending at the FDA (#msg-51012919) and EMA (#msg-39836037); in the former case, the application was resubmitted following a Refusal to File letter.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today